A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

8304A041703-NCT03739814OpenA Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory DiseaseA041703NCT03739814NationalAdultTreatmentIINationalLymphoid LeukemiaDoucette, KimberleyGeorgetown University Medical Center : Courtney Brown; Lombardi Comprehensive Cancer Center : Courtney BrownLeukemiaOncology GroupLombardi Comprehensive Cancer Center (LCCC)17339Courtney BrownCourtney Browncb1974@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>